Skip to Content
Merck
  • Non-stem cell lineages as an alternative origin of intestinal tumorigenesis in the context of inflammation.

Non-stem cell lineages as an alternative origin of intestinal tumorigenesis in the context of inflammation.

Nature genetics (2024-06-21)
Mathijs P Verhagen, Rosalie Joosten, Mark Schmitt, Niko Välimäki, Andrea Sacchetti, Kristiina Rajamäki, Jiahn Choi, Paola Procopio, Sara Silva, Berdine van der Steen, Thierry P P van den Bosch, Danielle Seinstra, Annemarie C de Vries, Michail Doukas, Leonard H Augenlicht, Lauri A Aaltonen, Riccardo Fodde
ABSTRACT

According to conventional views, colon cancer originates from stem cells. However, inflammation, a key risk factor for colon cancer, has been shown to suppress intestinal stemness. Here, we used Paneth cells as a model to assess the capacity of differentiated lineages to trigger tumorigenesis in the context of inflammation in mice. Upon inflammation, Paneth cell-specific Apc mutations led to intestinal tumors reminiscent not only of those arising in patients with inflammatory bowel disease, but also of a larger fraction of human sporadic colon cancers. The latter is possibly because of the inflammatory consequences of western-style dietary habits, a major colon cancer risk factor. Machine learning methods designed to predict the cell-of-origin of cancer from patient-derived tumor samples confirmed that, in a substantial fraction of sporadic cases, the origins of colon cancer reside in secretory lineages and not in stem cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-BEST4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Tamoxifen, ≥99%